Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?

Sofia Genta, Gloria Mittica, Gaia Giannone, Eleonora Ghisoni, Giorgio Valabrega

Research output: Contribution to journalArticle

Abstract

Endocrine therapy is the mainstay of treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Patients with metastatic disease may experience long lasting clinical benefit (CB) despite the line of endocrine therapy. The major limitation of this treatment is primary and, most frequently, acquired resistance. A better understanding of endocrine resistance has resulted in the development of new targeted agents to be integrated with endocrine therapy. The addition of a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor such as ribociclib (MONALEESA-2 trial) or palbociclib (PALOMA-3 trial) to endocrine treatment improved response rate (RR), and prolonged progression-free survival (PFS), but overall survival (OS) data are not yet available. Combination therapy with CDK4/6 inhibitors allows delaying conventional chemotherapy start but increases toxicities and costs. Identification and validation of biomarkers of response that could avoid unnecessary toxicities to patients are therefore essential. Ongoing and future trials will hopefully elucidate the optimal placement of CDK4/6 inhibitors in the treatment of HR+/HER2-BC.

Original languageEnglish
Pages (from-to)S197-S200
JournalTranslational Cancer Research
Volume6
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Estrogen Receptors
Breast Neoplasms
Therapeutics
Disease-Free Survival
Biomarkers
Hormones
Costs and Cost Analysis
Drug Therapy

Keywords

  • Breast cancer (BC)
  • CDK4/6 inhibitors
  • Endocrine resistance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? / Genta, Sofia; Mittica, Gloria; Giannone, Gaia; Ghisoni, Eleonora; Valabrega, Giorgio.

In: Translational Cancer Research, Vol. 6, 01.01.2017, p. S197-S200.

Research output: Contribution to journalArticle

@article{bd13a1f337d545aabbcf6cd0e84b3874,
title = "Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?",
abstract = "Endocrine therapy is the mainstay of treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Patients with metastatic disease may experience long lasting clinical benefit (CB) despite the line of endocrine therapy. The major limitation of this treatment is primary and, most frequently, acquired resistance. A better understanding of endocrine resistance has resulted in the development of new targeted agents to be integrated with endocrine therapy. The addition of a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor such as ribociclib (MONALEESA-2 trial) or palbociclib (PALOMA-3 trial) to endocrine treatment improved response rate (RR), and prolonged progression-free survival (PFS), but overall survival (OS) data are not yet available. Combination therapy with CDK4/6 inhibitors allows delaying conventional chemotherapy start but increases toxicities and costs. Identification and validation of biomarkers of response that could avoid unnecessary toxicities to patients are therefore essential. Ongoing and future trials will hopefully elucidate the optimal placement of CDK4/6 inhibitors in the treatment of HR+/HER2-BC.",
keywords = "Breast cancer (BC), CDK4/6 inhibitors, Endocrine resistance",
author = "Sofia Genta and Gloria Mittica and Gaia Giannone and Eleonora Ghisoni and Giorgio Valabrega",
year = "2017",
month = "1",
day = "1",
doi = "10.21037/tcr.2017.02.20",
language = "English",
volume = "6",
pages = "S197--S200",
journal = "Translational Cancer Research",
issn = "2218-676X",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?

AU - Genta, Sofia

AU - Mittica, Gloria

AU - Giannone, Gaia

AU - Ghisoni, Eleonora

AU - Valabrega, Giorgio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Endocrine therapy is the mainstay of treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Patients with metastatic disease may experience long lasting clinical benefit (CB) despite the line of endocrine therapy. The major limitation of this treatment is primary and, most frequently, acquired resistance. A better understanding of endocrine resistance has resulted in the development of new targeted agents to be integrated with endocrine therapy. The addition of a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor such as ribociclib (MONALEESA-2 trial) or palbociclib (PALOMA-3 trial) to endocrine treatment improved response rate (RR), and prolonged progression-free survival (PFS), but overall survival (OS) data are not yet available. Combination therapy with CDK4/6 inhibitors allows delaying conventional chemotherapy start but increases toxicities and costs. Identification and validation of biomarkers of response that could avoid unnecessary toxicities to patients are therefore essential. Ongoing and future trials will hopefully elucidate the optimal placement of CDK4/6 inhibitors in the treatment of HR+/HER2-BC.

AB - Endocrine therapy is the mainstay of treatment for most hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC). Patients with metastatic disease may experience long lasting clinical benefit (CB) despite the line of endocrine therapy. The major limitation of this treatment is primary and, most frequently, acquired resistance. A better understanding of endocrine resistance has resulted in the development of new targeted agents to be integrated with endocrine therapy. The addition of a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor such as ribociclib (MONALEESA-2 trial) or palbociclib (PALOMA-3 trial) to endocrine treatment improved response rate (RR), and prolonged progression-free survival (PFS), but overall survival (OS) data are not yet available. Combination therapy with CDK4/6 inhibitors allows delaying conventional chemotherapy start but increases toxicities and costs. Identification and validation of biomarkers of response that could avoid unnecessary toxicities to patients are therefore essential. Ongoing and future trials will hopefully elucidate the optimal placement of CDK4/6 inhibitors in the treatment of HR+/HER2-BC.

KW - Breast cancer (BC)

KW - CDK4/6 inhibitors

KW - Endocrine resistance

UR - http://www.scopus.com/inward/record.url?scp=85014125050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014125050&partnerID=8YFLogxK

U2 - 10.21037/tcr.2017.02.20

DO - 10.21037/tcr.2017.02.20

M3 - Article

AN - SCOPUS:85014125050

VL - 6

SP - S197-S200

JO - Translational Cancer Research

JF - Translational Cancer Research

SN - 2218-676X

ER -